<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Apomorphine" /><meta name="IX" content="Apomorphine" /><title>Apomorphine: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="208009.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="208009.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=208009.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2055.htm">4 Central nervous system</a> &gt; <a href="3631.htm">4.9 Drugs used in parkinsonism and related disorders</a> &gt; <a href="3632.htm">4.9.1 Dopaminergic drugs used in Parkinson’s disease</a> &gt; <a href="129827.htm">Dopamine-receptor agonists</a> &gt; <a href="10071.htm">APOMORPHINE HYDROCHLORIDE</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="129827.htm" title="Previous: Dopamine-receptor agonists">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="3646.htm" title="Next: BROMOCRIPTINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a304022.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine Hydrochloride</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Central Nervous System Agents 28:00 &gt; Antiparkinsonian Agents 28:36 &gt; Dopamine Receptor Agonists 28:36.20 &gt; Nonergot-derivative Dopamine Receptor Agonists 28:36.20.08</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22561-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Apomorphine</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: A &gt; Interactions of Apomorphine</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="129827.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dopamine-receptor agonists</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 4 Central nervous system &gt; 4.9 Drugs used in parkinsonism and related disorders &gt; 4.9.1 Dopaminergic drugs used in Parkinson’s disease</p></div></li><li><a href="10071.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">APOMORPHINE HYDROCHLORIDE</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 4 Central nervous system &gt; 4.9 Drugs used in parkinsonism and related disorders &gt; 4.9.1 Dopaminergic drugs used in Parkinson’s disease &gt; Dopamine-receptor agonists</p></div></li><li><a href="10074.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">APO-go®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 4 Central nervous system &gt; 4.9 Drugs used in parkinsonism and related disorders &gt; 4.9.1 Dopaminergic drugs used in Parkinson’s disease &gt; Dopamine-receptor agonists &gt; APOMORPHINE HYDROCHLORIDE</p></div></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK0122.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; A</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a504004.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine Hydrochloride</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; A</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0001s0292.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine Hydrochloride</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; A</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/A19-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine hydrochloride</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; A</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/4543-p.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine Hydrochloride</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antiparkinsonian Drugs &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/00746.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Apomorphine</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; A &gt; AP</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E2E3E0R0D130.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Apomorphine</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; A</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_10071">APOMORPHINE HYDROCHLORIDE</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i430.htm" title="Go to appendix 1">Apomorphine</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">refractory motor fluctuations in Parkinson’s disease (‘off’ episodes)
inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics
(for capable and motivated patients under specialist supervision)</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">see <a title="monograph-family: Dopamine receptor agonists" href="129827.htm#_129827">notes above</a>; pulmonary disease, cardiovascular disease, history of postural hypotension (special care on initiation); susceptibility to QT-interval prolongation; neuropsychiatric conditions; monitor hepatic, haemopoietic, renal, and cardiovascular function; <i>with concomitant <span>levodopa</span> </i> test initially and every 6 months for haemolytic anaemia
and thrombocytopenia (development
calls for specialist haematological care with dose reduction and possible
discontinuation); <b>interactions:</b> Appendix 1 (apomorphine)</p></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">respiratory depression, dementia, hypersensitivity to opioids, psychosis; avoid if ‘on’ response to levodopa marred by severe
dyskinesia or dystonia</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">avoid</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">use with caution</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">avoid unless clearly necessary</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">no information available; may suppress lactation</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">see <a title="BNF:monograph-family: Dopamine-receptor agonists" href="129827.htm#_129827">notes above</a>; also
nausea, vomiting (see <a title="BNF:target-block: Apomorphine guidance" href="129827.htm#_213651">notes above</a>); yawning; drowsiness (including
sudden onset of sleep), confusion, hallucinations; <i>less commonly</i> postural hypotension, dyspnoea, dyskinesia during ‘on’ periods (may
require discontinuation), haemolytic anaemia and thrombocytopenia
with levodopa (see Cautions), and rash; <i>rarely</i> eosinophilia;
peripheral oedema, compulsive behaviour (see <a title="BNF:target-text: Impulse control disorder caution" href="129827.htm#_211435">notes above</a>), and
dizziness also reported</p></div><div class="cAF"><h2>Dose</h2> <p class="cR"><span class="cU">By subcutaneous injection</span>, <span class="cAK">adult</span> over 18 years, to determine threshold dose
(see also <a title="BNF:target-block: Apomorphine guidance" href="129827.htm#_213651">notes above</a>), initially 1 mg at the first sign
of ‘off’ episode; if inadequate or no response after 30 minutes, then
a further 2 mg should be given; thereafter increase dose at minimum
40-minute intervals until satisfactory response obtained; usual range
3–30 mg daily in divided doses; subcutaneous infusion may be preferable
in those requiring division of injections into more than 10 doses
daily; max. single dose 10 mg</p><p class="cR"><span class="cU">By continuous subcutaneous infusion</span>, <span class="cAK">adult</span> over 18 years, (those requiring division into
more than 10 injections daily) initially 1 mg/hour increased according
to response (not more often than every 4 hours) in max. steps of 500 micrograms/hour,
to usual rate of 1–4 mg/hour (15–60 micrograms/kg/hour); change infusion
site every 12 hours and give during waking hours only (tolerance may
occur unless there is a 4-hour treatment-free period at night—24-hour
infusions not recommended unless severe night-time symptoms); intermittent
bolus doses may be needed</p><div class="cAR"><h3>Note</h3> <p class="cAX">Total daily dose by either route (or combined
routes) max. 100 mg</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li class="jN" id="_208009" style="margin: 0 0 0 20px;"><h1 class="title">Apomorphine<span> (Non-proprietary)</span> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Injection</span>, apomorphine hydrochloride
10 mg/mL, net price 2-mL amp = £6.08, 5-mL amp = £11.70. 
    Label:
    10, counselling, driving,
see <a title="BNF:target-block: Dopamine receptor agonists and driving" href="129827.htm#_213600">notes above</a></div></li><li><a href="10074.htm#_10074" title="APO-go®">APO-go®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="129827.htm">Previous: Dopamine-receptor agonists</a> | <a class="top" href="208009.htm#">Top</a> | <a accesskey="]" href="3646.htm">Next: BROMOCRIPTINE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>